Stocks Health care AKTX

NASDAQ · Health care

Akari Therapeutics Plc (AKTX)

It posted a net loss of $31M. At June 30, 2026 it held $7.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Akari Therapeutics Plc does

Akari Therapeutics Plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Akari Therapeutics Plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Quarterly results 8-K
2. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
3. August 12, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. August 7, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. July 10, 2026
   Shelf registration to sell securities (amended) S-3/A
6. July 8, 2026
   Shelf registration to sell securities (amended) S-3/A
7. July 2, 2026
   Shareholder vote results 8-K
8. July 2, 2026
   Shelf registration to sell securities S-3
9. June 26, 2026
   Material agreement 8-K
10. June 26, 2026
    IPO registration (amended) S-1/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 19, 2026. Insider transactions on SEC

Insider trades

What the people running Akari Therapeutics Plc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns AKTX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 121,550 shares in total, about $1.2M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about AKTX

What does Akari Therapeutics Plc do?

Akari Therapeutics Plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTX.

Is Akari Therapeutics Plc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $31M.

When did Akari Therapeutics Plc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 19, 2026.

Similar companies

Compare AKTX with

Compare AKTX with any company

Follow AKTX

Get an email when Akari Therapeutics Plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow AKTX: get an email when it files

Where the numbers come from

Financial figures are the values Akari Therapeutics Plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.